----item----
version: 1
id: {962EB7EF-9ADE-4701-943F-9052D263133D}
database: master
path: /sitecore/content/Pharma/MedtechInsight/Home/Articles/1995/05/15/Guerbet looks for 10 growth in 1995
parent: {166B4D89-6B6A-4D16-8DA9-761C7F941ECD}
name: Guerbet looks for 10 growth in 1995
master: {00000000-0000-0000-0000-000000000000}
template: {11380B5D-3531-4570-B213-EFC5312266E4}
templatekey: Article

----field----
field: {A4F985D9-98B3-4B52-AAAF-4344F6E747C6}
name: __Workflow
key: __workflow
content-length: 38

{926E6200-EB76-4AD4-8614-691D002573AC}
----version----
language: en
version: 1
revision: 14b2c011-f24a-4dc2-a550-3406fa05945b

----field----
field: {5BA0578F-65B7-4C22-8233-1603D698D8A4}
name: Summary
key: summary
content-length: 501

<p>Profits at French contrast media manufacturer <strong>[C#198700114:Guerbet]</strong> were up 9.2% to Fr 56 million ($11.4 million) in 1994 compared with 1993. Group turnover for the year was Fr 936.8 million, a rise of 3%, while R&D spending, which represented some 11% of revenues, totalled Fr 109 million. The company is expecting more rapid growth in 1995 than last year with larger profits in spite of product launches, says board president Dr Michel Guerbet in the company's annual report.</p>
----field----
field: {2D750EFF-9058-4ABF-A7FF-57FFE5DA1E3C}
name: Title
key: title
content-length: 36

Guerbet looks for 10% growth in 1995
----field----
field: {446A339B-E1D9-4DE1-8B5E-DB7942EF1723}
name: Body
key: body
content-length: 1504

<p>Profits at French contrast media manufacturer <strong>[C#198700114:Guerbet]</strong> were up 9.2% to Fr 56 million ($11.4 million) in 1994 compared with 1993. Group turnover for the year was Fr 936.8 million, a rise of 3%, while R&D spending, which represented some 11% of revenues, totalled Fr 109 million. The company is expecting more rapid growth in 1995 than last year with larger profits in spite of product launches, says board president Dr Michel Guerbet in the company's annual report.</p><pre>Guerbet (Fr millions) 1994 1993 % change Turnover 936.8 909.4 +3% Net profits 56.0 51.3 +9.2%</pre><p>Sales in France increased 7%, while European sales rose 10% compared with 1993, says the report. The company is present in 70% of the direct European market. In 1994, the company created a Turkish subsidiary and is seeking distributors in the UK, Italy and Spain. Currently, 76% of its products are distributed through Guerbet subsidiaries and the remainder through agents.</p><p>New products in the company's portfolio include its X-ray contrast agent Xenetix, already introduced in French hospitals and set for European launch in 1996; and Endorem, its MRI liver contrast agent, which was introduced in Germany in January (see Clinica No 645, p 22) and has also received marketing approval in France and Switzerland. Guerbet also hopes to launch Xenetix in the US in 1998 and in Japan in 1999. Sales of Hexabrix, Guerbet's interventional cardiology agent, rose 5% in the US during the year.</p>
----field----
field: {0212FC0F-953B-461C-B4D9-B7483A4D4F1B}
name: Taxonomy
key: taxonomy
content-length: 272

{6DDF7877-FDAE-472B-8739-FB4710DF7651}|{3A5E806F-C17B-4751-9A9A-7717F936EE6A}|{B2967A9C-ABDA-4628-A672-9EDDCD142AEA}|{32C2DFCA-405E-43AB-88A5-3883EB932000}|{F5161CC2-772F-472E-A21C-BF196343462E}|{FC1DA89F-D8A0-415D-99B6-86FF397EC709}|{2EDCC1FF-26E4-4C6E-AF73-0F43F0F033B8}
----field----
field: {8F4EE718-6FA0-42A5-85C4-6C8FE8B1FCD4}
name: Navigation Title
key: navigation title
content-length: 35

Guerbet looks for 10 growth in 1995
----field----
field: {7C4FC796-1311-4DAA-81AC-85EAA2C1C108}
name: Actual Publish Date
key: actual publish date
content-length: 15

19950515T000000
----field----
field: {BDF7C8E1-869E-49FF-B9F5-854B3081A45D}
name: Created Date
key: created date
content-length: 15

19950515T000000
----field----
field: {C926A72A-39DA-446D-B78C-2A650F820A73}
name: Modified Date
key: modified date
content-length: 15

19950515T000000
----field----
field: {1616FE67-7278-4169-948E-C29B00EC8781}
name: Article Number
key: article number
content-length: 8

MT052649
----field----
field: {2C985172-2B37-4CFE-AEDE-2A42EC833941}
name: Content Type
key: content type
content-length: 38

{832554E5-EC9E-4747-8623-6770D36CAF32}
----field----
field: {31603F25-6D9C-4954-BCDE-342E1E184A30}
name: Meta Title Override
key: meta title override
content-length: 36

Guerbet looks for 10% growth in 1995
----field----
field: {53288D3D-66D7-4ACE-B3E4-D7D02B1F3672}
name: Referenced Companies
key: referenced companies
content-length: 9

198700114
----field----
field: {AE1BD751-D4E7-49CB-96C4-62E995A06B51}
name: Article Category
key: article category
content-length: 4

News
----field----
field: {0F6C8F42-01DC-4E05-B63E-AA25D8AA0E09}
name: Legacy Publication
key: legacy publication
content-length: 38

{FF38DC83-07D4-43F0-8C55-84EB64FAF35A}
----field----
field: {5795FF15-0942-41FF-8A77-3B73185F5E1B}
name: Escenic ID
key: escenic id
content-length: 6

254458
----field----
field: {25BED78C-4957-4165-998A-CA1B52F67497}
name: __Created
key: __created
content-length: 16

20160622T184239Z
----field----
field: {5DD74568-4D4B-44C1-B513-0AF5F4CDA34F}
name: __Created by
key: __created by
content-length: 18

sitecore\Anonymous
----field----
field: {8CDC337E-A112-42FB-BBB4-4143751E123F}
name: __Revision
key: __revision
content-length: 36

14b2c011-f24a-4dc2-a550-3406fa05945b
----field----
field: {D9CF14B1-FA16-4BA6-9288-E8A174D4D522}
name: __Updated
key: __updated
content-length: 16

20160622T184239Z
----field----
field: {BADD9CF9-53E0-4D0C-BCC0-2D784C282F6A}
name: __Updated by
key: __updated by
content-length: 18

sitecore\Anonymous
----field----
field: {3E431DE1-525E-47A3-B6B0-1CCBEC3A8C98}
name: __Workflow state
key: __workflow state
content-length: 38

{962542F5-554E-4DE8-BE4C-B0796FDAC854}
